by | May 4, 2024 | Publications
J Clin Oncol. 2024 May 3:JCO2300934. doi: 10.1200/JCO.23.00934. Online ahead of print. ABSTRACT PURPOSE: Prognostic Immunophenotyping in Myeloma Response (PRIMeR) is an ancillary study of minimal residual disease (MRD) assessment for multiple myeloma by...
by | May 3, 2024 | Publications
Cancer Med. 2024 May;13(9):e7232. doi: 10.1002/cam4.7232. ABSTRACT BACKGROUND: Comparative investigations evaluating the efficacy of pomalidomide-based (Pom-based) versus daratumumab-based (Dara-based) therapies in patients with relapsed/refractory multiple myeloma...
by | May 3, 2024 | Publications
Heliyon. 2024 Apr 21;10(9):e29997. doi: 10.1016/j.heliyon.2024.e29997. eCollection 2024 May 15. ABSTRACT Multiple myeloma (MM), marked by abnormal proliferation of plasma cells and production of monoclonal immunoglobulin heavy or light chains in the majority of...
by | May 3, 2024 | Publications
J Pain Res. 2024 Apr 24;17:1571-1581. doi: 10.2147/JPR.S448634. eCollection 2024. ABSTRACT BACKGROUND: Peripheral neuropathy (PN) is a prevalent complication of multiple myeloma (MM), due to the disease itself or its treatment. Despite extensive research, the optimal...
by | May 3, 2024 | Publications
medRxiv [Preprint]. 2024 Apr 19:2024.04.19.24306082. doi: 10.1101/2024.04.19.24306082. ABSTRACT BACKGROUND: Early therapeutic intervention in high-risk SMM (HR-SMM) has demonstrated benefit in previous studies of lenalidomide with or without dexamethasone. Triplets...
by | May 3, 2024 | Publications
Heliyon. 2024 Apr 20;10(8):e30123. doi: 10.1016/j.heliyon.2024.e30123. eCollection 2024 Apr 30. ABSTRACT BACKGROUND: Tumor genetic anomalies and immune dysregulation are pivotal in the progression of multiple myeloma (MM). Accurate patient stratification is essential...
